SQUID Liquid Embolic Agent (LEA)
Balt USA, LLC · Decision date Oct 16, 2026
What did the FDA approve?
The FDA record for P250009/S001, dated 2026-10-16, shows approval of the protocol for the COSMIC post-approval study, submitted under the normal 180-day track with no user fee. The supplement reason is listed as Postapproval Study Protocol, tied to the SQUID Liquid Embolic Agent (LEA), product code SGU, in neurology, submitted by Balt USA, LLC. The record does not describe the protocol's design, endpoints, sample size, or the conditions it addresses.
The source statement indicates the protocol was submitted to comply with conditions of approval in the original P250009 order. That wording is the agency's reported purpose, not independent evidence of safety or clinical effectiveness. The record does not show a change to the device's indications or labeling, and the six-character identifier alone does not confirm the original approval date or the full scope of the parent PMA. The decision applies to the PAS protocol, not a new approval of the whole system.
FDA approval order statement
Approval of the protocol for the COSMIC post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250009.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Oct 16, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250009/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Balt USA, LLC
- Product code
- SGU
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Neurovascular Liquid Embolic Agent.
- Applicant
- Balt USA, LLC
- Product code
- SGU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250009 · Original PMA
SQUID Liquid Embolic Agent (LEA)
P250009/S001 received
Application receipt date recorded by FDA.
P250009/S002 · Related supplement
SQUID Liquid Embolic Agent (LEA)
P250009/S001 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Balt USA, LLC | PMA approval | Jan 30, 2026 | FDA | |
SQUID Liquid Embolic Agent (LEA)P250009/S002 | Balt USA, LLC | PMA supplement | Sep 9, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Balt USA, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 29 Parker, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250009/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
